Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2010, Article ID 537673, 7 pages
http://dx.doi.org/10.4061/2010/537673
Review Article

Osteoporosis Syndrome in Thalassaemia Major: An Overview

Paediatric Endocrine Unit, Department of Paediatrics, Makarios Hospital, 1474 Nicosia, Cyprus

Received 15 January 2010; Accepted 4 March 2010

Academic Editor: Manuel Diaz Curiel

Copyright © 2010 Meropi Toumba and Nicos Skordis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Di Stefano, P. Chiabotto, C. Roggia et al., “Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs,” Journal of Bone and Mineral Metabolism, vol. 22, no. 1, pp. 53–57, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Voskaridou and E. Terpos, “New insights into the pathophysiology and management of osteoporosis in patients with β thalassaemia,” British Journal of Haematology, vol. 127, no. 2, pp. 127–139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Skordis, E. Efstathiou, A. Kyriakou, and M. Toumba, “Hormonal dysregulation and bones in thalassaemia—an overview,” Pediatric Endocrinology Reviews, vol. 6, supplement 1, pp. 107–115, 2008. View at Google Scholar · View at Scopus
  4. N. F. Olivieri, G. Koren, J. Harris et al., “Growth failure and bony changes induced by deferoxamine,” American Journal of Pediatric Hematology/Oncology, vol. 14, no. 1, pp. 48–56, 1992. View at Google Scholar · View at Scopus
  5. S. De Virgiliis, M. Congia, F. Frau et al., “Deferoxamine-induced growth retardation in patients with thalassemia major,” Journal of Pediatrics, vol. 113, no. 4, pp. 661–669, 1988. View at Google Scholar · View at Scopus
  6. D. Vega, N. M. Maalouf, and K. Sakhaee, “The role of receptor activator of nuclear factor-κB (RANK)/RANK ligand/osteoprotegerin: clinical implication,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 12, pp. 4514–4521, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. O. S. Salama, Y. A. Al-Tonbary, R. A. Shahin, and O. A. Sharaf Eldeen, “Unbalanced bone turnover in children with β-thalassemia,” Hematology, vol. 11, no. 3, pp. 197–202, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Voskaridou, M.-C. Kyrtsonis, E. Terpos et al., “Bone resorption is increased in young adults with thalassaemia major,” British Journal of Haematology, vol. 112, no. 1, pp. 36–41, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Voskaridou, E. Terpos, G. Spina et al., “Pamidronate is an effective treatment for osteoporosis in patients with ß-thalassaemia,” British Journal of Haematology, vol. 123, no. 4, pp. 730–737, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Dresner-Pollak, E. Rachmilewitz, A. Blumenfeld, M. Idelson, and A. W. Goldfarb, “Bone mineral metabolism in adults with β-thalassaemia major and intermedia,” British Journal of Haematology, vol. 111, no. 3, pp. 902–907, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Lasco, N. Morabito, A. Gaudio, M. Buemi, M. Wasniewska, and N. Frisina, “Effects of hormonal replacement therapy on bone metabolism in young adults with β-thalassemia major,” Osteoporosis International, vol. 12, no. 7, pp. 570–575, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Morabito, A. Gaudio, A. Lasco et al., “Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle,” Journal of Bone and Mineral Research, vol. 19, no. 5, pp. 722–727, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. B. L. Riggs, “The mechanisms of estrogen regulation of bone resorption,” Journal of Clinical Investigation, vol. 106, no. 10, pp. 1203–1204, 2000. View at Google Scholar · View at Scopus
  14. W. P. Olszynski, K. Shawn Davison, J. D. Adachi et al., “Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment,” Clinical Therapeutics, vol. 26, no. 1, pp. 15–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. C. E. Jensen, S. M. Tuck, J. E. Agnew et al., “High prevalence of low bone mass in thalassaemia major,” British Journal of Haematology, vol. 103, no. 4, pp. 911–915, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Skordis, M. Michaelidou, S. C. Savva et al., “The impact of genotype on endocrine complications in thalassaemia major,” European Journal of Haematology, vol. 77, no. 2, pp. 150–156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. L. Anapliotou, I. T. Kastanias, P. Psara, E. A. Evangelou, M. Liparaki, and P. Dimitriou, “The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches,” Clinical Endocrinology, vol. 42, no. 3, pp. 279–287, 1995. View at Google Scholar · View at Scopus
  18. M. Mylona, M. Leotsinides, T. Alexandrides, N. Zoumbos, and P. A. Dimopoulos, “Comparison of DXA, QCT and trabecular structure in β-thalassaemia,” European Journal of Haematology, vol. 74, no. 5, pp. 430–437, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. Italian Working Group on Endocrine Complications in Non-Endocrine Diseases, “Multi-centre study on prevalence of endocrine complications in thalassaemia major,” Clinical Endocrinology, vol. 42, no. 6, pp. 581–586, 1995. View at Google Scholar
  20. N. Skordis, L. Petrikkos, M. Toumba et al., “Update on fertility in thalassaemia major,” Pediatric Endocrinology Reviews, vol. 2, supplement 2, pp. 296–302, 2004. View at Google Scholar · View at Scopus
  21. M. Toumba, A. Sergis, C. Kanaris, and N. Skordis, “Endocrine complications in patients with thalassaemia major,” Pediatric Endocrinology Reviews, vol. 5, no. 2, pp. 642–648, 2007. View at Google Scholar · View at Scopus
  22. V. De Sanctis, C. Vullo, M. Katz, B. Wonke, R. Tanas, and B. Bagni, “Gonadal function in patients with β-thalassaemia major,” Journal of Clinical Pathology, vol. 41, no. 2, pp. 133–137, 1988. View at Google Scholar · View at Scopus
  23. D. Perera, A. Pizzey, A. Campbell et al., “Sperm DNA damage in potentially fertile homozygous ß-thalassaemia patients with iron overload,” Human Reproduction, vol. 17, no. 7, pp. 1820–1825, 2002. View at Google Scholar · View at Scopus
  24. M. Berkovitch, T. Bistritzer, S. D. Milone, K. Perlman, W. Kucharczyk, and N. F. Olivieri, “Iron deposition in the anterior pituitary in homozygous β-thalassemia: MRI evaluation and correlation with gonadal function,” Journal of Pediatric Endocrinology and Metabolism, vol. 13, no. 2, pp. 179–184, 2000. View at Google Scholar · View at Scopus
  25. A. Filosa, S. Di Maio, S. Vocca, A. Saviano, G. Esposito, and L. Pagano, “Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis,” Acta Paediatrica, vol. 86, no. 4, pp. 342–346, 1997. View at Google Scholar · View at Scopus
  26. R. Lala, P. Chiabotto, M. Di Stefano, G. C. Isaia, F. Garofalo, and A. Piga, “Bone density and metabolism in thalassaemia,” Journal of Pediatric Endocrinology and Metabolism, vol. 11, supplement 3, pp. 785–790, 1998. View at Google Scholar · View at Scopus
  27. B. K. Bielinski, P. J. Darbyshire, L. Mathers et al., “Impact of disordered puberty on bone density in β-thalassaemia major,” British Journal of Haematology, vol. 120, no. 2, pp. 353–358, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Mahachoklertwattana, V. Sirikulchayanonta, A. Chuansumrit et al., “Bone histomorphometry in children and adolescents with ß-thalassemia disease: iron-associated focal osteomalacia,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 8, pp. 3966–3972, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Benigno, S. Bertelloni, G. I. Baroncelli et al., “Effects of thalassemia major on bone mineral density in late adolescence,” Journal of Pediatric Endocrinology and Metabolism, vol. 16, supplement 2, pp. 337–342, 2003. View at Google Scholar · View at Scopus
  30. E. Carmina, G. Di Fede, N. Napoli et al., “Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major,” Calcified Tissue International, vol. 74, no. 1, pp. 68–71, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Savine and P. Sönksen, “Growth hormone—hormone replacement for the somatopause?” Hormone Research, vol. 53, supplement 3, pp. 37–41, 2000. View at Google Scholar · View at Scopus
  32. M. Kassem, W. Blum, J. Ristelli, L. Mosekilde, and E. F. Eriksen, “Growth hormone stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro,” Calcified Tissue International, vol. 52, no. 3, pp. 222–226, 1993. View at Google Scholar · View at Scopus
  33. D. J. Digirolamo, A. Mukherjee, K. Fulzele et al., “Mode of growth hormone action in osteoblasts,” Journal of Biological Chemistry, vol. 282, no. 43, pp. 31666–31674, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Li, P. M. Bartold, C. Z. Zhang, R. W. Clarkson, W. G. Young, and M. J. Waters, “Growth hormone and insulin-like growth factor-1 induce bone morphogenetic proteins 2 and 4: a mediator role in bone and tooth formation,” Endocrinology, vol. 139, no. 9, pp. 3855–3862, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Mrak, I. Villa, R. Lanzi, M. Losa, F. Guidobono, and A. Rubinacci, “Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells,” Journal of Endocrinology, vol. 192, no. 3, pp. 639–645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. T. L. McCarthy, M. Centrella, and E. Canalis, “Regulatory effects of insulin-like growth factors I and II on bone collagen synthesis in rat calvarial cultures,” Endocrinology, vol. 124, no. 1, pp. 301–309, 1989. View at Google Scholar · View at Scopus
  37. H. Mochizuki, Y. Hakeda, N. Wakatsuki et al., “Insulin-like growth factor-I supports formation and activation of osteoclasts,” Endocrinology, vol. 131, no. 3, pp. 1075–1080, 1992. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Leger, R. Girot, H. Crosnier, M. C. Postel-Vinay, and R. Rappaport, “Normal growth hormone (GH) response to GH-releasing hormone in children with thalassemia major before puberty: a possible age-related effect,” Journal of Clinical Endocrinology and Metabolism, vol. 69, no. 2, pp. 453–456, 1989. View at Google Scholar · View at Scopus
  39. A. T. Soliman, N. El Banna, and B. M. Ansari, “GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with β-thalassaemia,” European Journal of Endocrinology, vol. 138, no. 4, pp. 394–400, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. G. DeLuca, M. Maggiolini, M. Bria et al., “GH secretion in thalassemic patients with short stature,” Hormone Research, vol. 44, no. 4, pp. 158–163, 1995. View at Google Scholar · View at Scopus
  41. V. De Sanctis, “Growth and puberty and its management in thalassaemia,” Hormone Research, vol. 58, supplement 1, pp. 72–79, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Shehadeh, A. Hazani, M. C. J. Rudolf, I. Peleg, A. Benderly, and Z. Hochberg, “Neurosecretory dysfunction of growth hormone secretion in thalassemia major,” Acta Paediatrica Scandinavica, vol. 79, no. 8–9, pp. 790–795, 1990. View at Google Scholar · View at Scopus
  43. H. Karamifar, M. Karimi, G. Amirhakimi, M. Sharbatialaei, and V. De Sanctis, “Reduced insulin growth factor I concentrations in iron-overloaded β thalassaemic patients with normal growth hormone secretion and liver function,” Pediatric Endocrinology Reviews, vol. 2, supplement 2, pp. 256–258, 2004. View at Google Scholar · View at Scopus
  44. B. P. Leheup, M. Cisternino, M. Bozzola et al., “Growth hormone response following growth hormone releasing hormone injection in thalassemia major: influence of pubertal development,” Journal of Endocrinological Investigation, vol. 14, no. 1, pp. 37–40, 1991. View at Google Scholar · View at Scopus
  45. M. Scacchi, L. Danesi, A. Cattaneo et al., “Bone demineralization in adult thalassaemic patients: contribution of GH and IGF-I at different skeletal sites,” Clinical Endocrinology, vol. 69, no. 2, pp. 202–207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. C. La Rosa, V. De Sanctis, A. Mangiagli et al., “Growth hormone secretion in adult patients with thalassaemia,” Clinical Endocrinology, vol. 62, no. 6, pp. 667–671, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Sartorio, G. Conte, A. Conti et al., “Effects of 12 months rec-GH therapy on bone and collagen turnover and bone mineral density in GH deficient children with thalassaemia major,” Journal of Endocrinological Investigation, vol. 23, no. 6, pp. 356–361, 2000. View at Google Scholar · View at Scopus
  48. N. G. Angelopoulos, A. Goula, G. Rombopoulos et al., “Hypoparathyroidism in transfusion-dependent patients with ß-thalassemia,” Journal of Bone and Mineral Metabolism, vol. 24, no. 2, pp. 138–145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Karimi, F. Habibzadeh, and V. De Sanctis, “Hypoparathyroidism with extensive intracerebral calcification in patients with β-thalassemia major,” Journal of Pediatric Endocrinology and Metabolism, vol. 16, no. 6, pp. 883–886, 2003. View at Google Scholar · View at Scopus
  50. L. Rioja, R. Girot, M. Garabédian, and G. Cournot-Witmer, “Bone disease in children with homozygous β-thalassemia,” Bone and Mineral, vol. 8, no. 1, pp. 69–86, 1990. View at Publisher · View at Google Scholar · View at Scopus
  51. S. De Virgiliis, M. Congia, F. Frau et al., “Deferoxamine-induced growth retardation in patients with thalassemia major,” Journal of Pediatrics, vol. 113, no. 4, pp. 661–669, 1988. View at Google Scholar · View at Scopus
  52. M. C. De Vernejoul, R. Girot, J. Gueris et al., “Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia,” Journal of Clinical Endocrinology and Metabolism, vol. 54, no. 2, pp. 276–281, 1982. View at Google Scholar · View at Scopus
  53. A. Moulas, A. Challa, N. Chaliasos, and P. D. Lapatsanis, “Vitamin D metabolites (25-hydroxyvitamin D, 24,25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D) and osteocalcin in β-thalassaemia,” Acta Paediatrica, vol. 86, no. 6, pp. 594–599, 1997. View at Google Scholar · View at Scopus
  54. G. Praticò, F. Di Gregorio, L. Caltabiano, G. M. Palano, M. Morana, and M. Caruso-Nicoletti, “Bone metabolism markers in thalassemia,” La Pediatria Medica e Chirurgica, vol. 23, no. 1, pp. 35–39, 2001. View at Google Scholar · View at Scopus
  55. A. Kyriakou, S. C. Savva, I. Savvides et al., “Gender differences in the prevalence and severity of bone disease in thalassaemia,” Pediatric Endocrinology Reviews, vol. 6, supplement 1, pp. 116–122, 2008. View at Google Scholar · View at Scopus
  56. R. Origa, E. Fiumana, M. R. Gamberini et al., “Osteoporosis in ß-thalassemia: clinical and genetic aspects,” Annals of the New York Academy of Sciences, vol. 1054, pp. 451–456, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Christoforidis, E. Hatzipantelis, I. Tsatra, G. Katzos, and M. Athanassiou-Metaxa, “Bone mineral density in children and young adults with β-thalassemia major conventionally treated,” Pediatric Blood and Cancer, vol. 47, no. 1, pp. 113–114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. F. Garofalo, A. Piga, R. Lala, S. Chiabotto, M. Di Stefano, and G. C. Isaia, “Bone metabolism in thalassemia,” Annals of the New York Academy of Sciences, vol. 850, pp. 475–478, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. A. A. Shamshirsaz, M. R. Bekheirnia, M. Kamgar et al., “Bone mineral density in Iranian adolescents and young adults with thalassemia major,” Pediatric Hematology and Oncology, vol. 24, no. 7, pp. 469–479, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Canatan, N. Akar, and A. Arcasoy, “Effects of calcitonin therapy on osteoporosis in patients with thalassemia,” Acta Haematologica, vol. 93, no. 1, pp. 20–24, 1995. View at Google Scholar · View at Scopus
  61. P. J. Meunier, P. D. Delmas, R. Eastell et al., “Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines,” Clinical Therapeutics, vol. 21, no. 6, pp. 1025–1044, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. N. Skordis, Y. S. Ioannou, A. Kyriakou et al., “Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major,” Pediatric Endocrinology Reviews, vol. 6, supplement 1, pp. 144–148, 2008. View at Google Scholar · View at Scopus
  63. E. Voskaridou and E. Terpos, “Pathogenesis and management of osteoporosis in thalassemia,” Pediatric Endocrinology Reviews, vol. 6, supplement 1, pp. 86–93, 2008. View at Google Scholar · View at Scopus